肺癌组织中p53和VEGF的表达及其临床意义(2)
 |
| 第1页 |
参见附件(1942KB，3页)。
[2] Hiyoshi H,Atsuno Y,Ato H,et al.Linicopathological significance f nuclear accumulation of tumor suppressor gene p53 product in pri-ary lung cancer. Jpn J Cancer Res,992,3(1):1-6.
[3] Wistuba U,Gazdar A F,Minna J D.Olocular genetics of small cell ung carcinoma.Senmin Onool,2001,28(2 Suppl4):S3.
[4] Niklinski J,Niklinska W, Chyczewski L,et al. Molecular genetic ab-normalities in prem alignant lung lesions:biological and clinical implica-tions. Eur J Cancer Prev,2001,10(3):213-226.
[5] Marchetti A, Buttitta F, Merlo G,et al. P53 alteration in non-smallcell lung cancers correlate with metastatic involvement of hilar and me-diastinal lymphnodes. Cancer Res,1993,53(12):2846-2851.
[6] 李印,车国卫,周清华,等. 肺癌中血管内皮生长因子及突变型P53基因表达及其临床意义研究.中国肺癌杂志,2001,4(5):371-373.
[7] Anderson M L, Spandidos D A. Oncogenes and onCO2 superssor genes in lung cancer. Respir Med, 1993,87(6):413-420.
[8] 赖百塘.血管内皮生长因子与肺癌. 结核病与胸部肿瘤,2001,(3):53-58.
[9] 王慧敏,廖美琳. 血管内皮生长因子对非小细胞肺癌术后生存率的影响.中国癌症杂志,2000,10(4):299-302.
[10] Ohta Y, Watanake Y, Murakami S, et al. Vascular endot helial growth factor and lymph node metastasis in primary lung cancer ......
您现在查看是摘要介绍页，详见PDF附件(1942KB，3页)。